London, 5 October 2026

MÈRERA Therapeutics participated in W Accelerate 2026 in London, an initiative bringing together emerging innovators in women’s health and reproductive medicine.

Represented by co-founders Dr Sanja Fitzgerald and Dr Daniel Fitzgerald, MÈRERA presented its vision for advancing reproductive medicine through precision protein therapeutics.

MÈRERA is developing innovative protein-based approaches to address age-related oocyte aneuploidy, a major biological challenge affecting reproductive outcomes in women of advanced maternal age.

The event provided an opportunity to connect with fellow innovators and industry professionals working to advance women’s health and fertility.

MÈRERA Therapeutics continues to progress its preclinical programme towards biological proof of concept.